SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that
Amit D. Munshi, the Company's
President and Chief Executive Officer, will present a corporate
update at the 8th Annual SVB Leerink Global Healthcare Conference
on Wednesday, February 27, 2019 at
9:30 AM EST. The conference will take
place February 27 – March 1, 2019 at the Lotte New York Palace in
New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune and inflammatory conditions, is being evaluated in
later-stage clinical programs in ulcerative colitis (UC) and
Crohn's disease, as well as in programs for other indications such
as atopic dermatitis. Arena is also evaluating olorinab (APD371) in
a Phase 2 program for gastrointestinal pain. Arena continues to
assess other earlier research and development stage drug
candidates, including APD418 for decompensated heart failure.
Arena's licensee, United Therapeutics, is evaluating ralinepag in a
Phase 3 program for pulmonary arterial hypertension (PAH).
Arena has additional license agreements and partnerships,
including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries),
Boehringer Ingelheim International GmbH (undisclosed target –
preclinical), Outpost Medicine, LLC (undisclosed target –
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "driven to," "potentially,"
"potential," "evaluating for," "being evaluated," "assess for," or
words of similar meaning, or they may be identified by the fact
that they do not relate strictly to historical or current facts.
Such forward-looking statements include, without limitation,
statements about Arena's upcoming presentation and audio webcast
and Arena's drive, focus, goals, strategy, clinical and research
and development programs, collaborations, and licenses. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include the timing and outcome of research, development
and regulatory review is uncertain; clinical programs may not
proceed at the time or in the manner expected or at all; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results; and
other risks related to developing and commercializing drugs; as
well as those factors disclosed in Arena's filings with the
Securities and Exchange Commission (SEC), including but not limited
to Arena's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2018, which was filed
with the SEC on November 8, 2018.
These forward-looking statements represent Arena's judgment as of
the time of this release. Arena disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Kevin
R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-on-february-27-300799306.html
SOURCE Arena Pharmaceuticals, Inc.